Tela Bio, Inc. Stock Price, News & Analysis

TELA Bio (NASDAQ: TELA) announced inducement equity awards approved by the Compensation Committee with a Grant Date of November 10, 2025 under Nasdaq Rule 5635(c)(4).

The awards consist of 30,200 restricted stock units granted to seventeen newly hired employees and a 25,000-share stock option granted to one employee. The option exercise price equals $1.19 per share (closing price on the Grant Date), the option term is 10 years, and vesting occurs over four years (25% at the first anniversary, then monthly over 36 months). The RSUs vest in equal annual installments over four years and all awards require continued service through vesting dates.

TELA Bio (NASDAQ: TELA) priced an underwritten registered direct offering on Nov 13, 2025 comprising 4,189,000 common shares at $1.11 per share and, in lieu of shares, 7,523,000 pre-funded warrants at $1.1099 each (exercise price $0.0001). The gross proceeds are expected to be approximately $13.0 million, before underwriting discounts and offering expenses, assuming no exercise of the pre-funded warrants. The offering is expected to close on or about Nov 17, 2025, subject to customary closing conditions.

Canaccord Genuity is sole bookrunner; the deal was led by Nantahala Capital and EW Healthcare Partners. Proceeds are intended for general corporate purposes, including sales and marketing, R&D, G&A, working capital and capital expenditures. The offering is being made under an SEC-declared Form S-3 shelf registration (File No. 333-275511).

TELA Bio (NASDAQ: TELA) reported third quarter 2025 results on November 13, 2025: Q3 revenue $20.7M, up 9% year-over-year, and gross margin 67.5%. Operating loss narrowed to $7.6M and net loss to $8.6M versus $9.4M and $10.4M in Q3 2024. Cash totaled $29.7M on September 30, 2025. The company revised full-year 2025 revenue guidance to at least +16% vs 2024. Subsequent to quarter end, TELA closed a Perceptive Advisors credit facility up to $70M (initial $60M drawn, additional $10M callable through April 30, 2027), maturing November 14, 2030, interest = 7.85% + max(1-month SOFR, 4.25%), interest-only until maturity.

TELA Bio (NASDAQ: TELA) will report third quarter 2025 financial results on Thursday, November 13, 2025.

Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a corporate update. Investors must register online at least one day in advance or at minimum 15 minutes before the call. A live webcast and a replay will be available on the company’s Events & Presentations page in Investor Relations.

TELA Bio (NASDAQ: TELA) announced on November 3, 2025 the appointment of William “Bill” Plovanic, CFA, to its Board of Directors.

Plovanic is Managing Director, Healthcare Equity Research at Canaccord Genuity and previously held C‑level operating and board roles at Obalon Therapeutics from 2016 to 2021. The company said his combination of capital markets expertise and hands‑on med‑tech operating experience will support corporate strategy and commercial execution as TELA Bio continues to develop soft‑tissue reconstruction solutions.

TELA Bio (NASDAQ: TELA) announced on October 9, 2025 the appointment of Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors and the departure of director Lisa Colleran after five years of service.

Dr. Rocchio is Executive Vice President and Chief Nurse Executive at Advocate Health, overseeing more than 42,000 nurses and leading enterprise nursing strategy across a six-state system; the company highlighted her expertise in group purchasing organizations and supply-chain alignment. Ms. Colleran, CEO of IC Surgical and former CEO of LifeCell, stepped down after contributing commercial leadership since 2020.

TELA Bio (NASDAQ:TELA) reported strong Q2 2025 financial results with revenue of $20.2 million, representing 26% year-over-year growth and 9% sequential growth. The company's OviTex and OviTex PRS products saw significant demand increases, with year-over-year revenue growth of 12% and 53% respectively.

The company appointed Jeffrey Blizard as President to strengthen commercial leadership and announced the European launch of OviTex Inguinal for robotic procedures. Despite a gross profit of $14.1 million (69.8% margin), TELA Bio recorded a net loss of $9.9 million, an improvement from the $12.6 million loss in Q2 2024.

TELA Bio reiterated its full-year 2025 revenue guidance of $85.0-88.0 million, projecting 23-27% growth. The company ended Q2 with $35.0 million in cash and cash equivalents.

TELA Bio (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has announced the approval of inducement grants to fourteen new employees. The Compensation Committee approved restricted stock units covering 10,200 shares of common stock, granted on August 5, 2025.

These grants, made under Nasdaq Rule 5635(c)(4), are part of the employees' compensation packages and will vest equally over four years, contingent on continued employment with TELA Bio.

TELA Bio (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's management team will deliver a presentation on August 13th, 2025, at 10:00 am ET. Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at ir.telabio.com.